Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia
BLOOD CELL THERAPY / The official journal of APBMT · 2024 · 7 (3)
DOI: 10.31547/bct-2024-005 ↗Kurz gefasst
Fallbericht in der Zeitschrift BLOOD CELL THERAPY / The official journal of APBMT, 2024. Verfasst von E Tamellini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Zitieren
APA
Tamellini, E., Sorio, M., Andreini, A., Tecchio, C., Nadali, G., Bernardelli, A., Ferrarini, I., Crosera, L., Vatteroni, A., Simio, C., Benedetti, F., Krampera, M., & Tanasi, I. (2024). Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia. BLOOD CELL THERAPY / The official journal of APBMT, 7(3). https://doi.org/10.31547/bct-2024-005
Vancouver
Tamellini E, Sorio M, Andreini A, Tecchio C, Nadali G, Bernardelli A, et al. Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia. BLOOD CELL THERAPY / The official journal of APBMT. 2024;7(3). doi:10.31547/bct-2024-005
BibTeX
@article{Tamellini2024,
author = {Tamellini, E and Sorio, M and Andreini, A and Tecchio, C and Nadali, G and Bernardelli, A and Ferrarini, I and Crosera, L and Vatteroni, A and Simio, C and Benedetti, F and Krampera, M and Tanasi, I},
title = {Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia},
journal = {BLOOD CELL THERAPY / The official journal of APBMT},
year = {2024},
volume = {7},
number = {3},
doi = {10.31547/bct-2024-005}
}
EUVIMED